Author

Nadim Kassem

Observed institutions: University of Southern California, University of Maryland, Baltimore, Brigham and Women's Hospital, Winthrop-University Hospital, Harvard University, Thomas Jefferson University, Savient Pharmaceuticals (United States)

OpenAlex ID: A5110146865

Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial

2005 · Andrew IR Maas, Gordon Murray, et al. · The Lancet Neurology · 284

Safety and Pharmacokinetics of Multiple Doses of Recombinant Human CuZn Superoxide Dismutase Administered Intratracheally to Premature Neonates With Respiratory Distress Syndrome

1997 · Jonathan M. Davis, Warren N. Rosenfeld, et al. · PEDIATRICS · 129

Safety and Pharmacokinetics of Recombinant Human Superoxide Dismutase Administered Intratracheally to Premature Neonates With Respiratory Distress Syndrome

1996 · Warren N. Rosenfeld, Jonathan M. Davis, et al. · PEDIATRICS · 85

Long-Term Follow-up of Premature Infants Treated With Prophylactic, Intratracheal Recombinant Human CuZn Superoxide Dismutase

2000 · Jonathan M Davis, Susan E Richter, et al. · Journal of Perinatology · 43

322 Biological and clinical properties of antiandrogens

1983 · Rudolph Neri, Nadim Kassem · Journal of Steroid Biochemistry · 24

Pharmacodynamics of intravenous labetalol and follow-up therapy with oral labetalol

1985 · Nicholas D Vlachakis, Robert F Maronde, et al. · Clinical Pharmacology & Therapeutics · 15

Long Term Follow-up of Premature Infants Treated with Prophylactic, Intratracheal Recombinant Human CuZn Superoxide Dismutase (rhSOD) ♦ 1211

1998 · Saumitra Biswas, Susan E Richter, et al. · Pediatric Research · 3

735 Progress in Clinical Development of Dexanabinol for Traumatic Brain Injury

2001 · Anat Biegon, Nachshon Knoller, et al. · Neurosurgery

Works count: 8

Citation count: 583

H-index: 6

I10-index: 6